Chris LeMasters
Founder at Hoosier Oncology Group, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Samuel Ellis | M | - |
January Therapeutics, Inc.
 January Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services January Therapeutics, Inc. provides biotechnology services. The company was founded by Robin Jackman and Neil Raheja and is headquartered in San Diego, CA. | - |
| Qing Dong | M | - |
Xinthera, Inc.
 Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | 3 years |
| Elaine Heron | M | 76 |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 15 years |
| Paul Grint | M | 66 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.
January Therapeutics, Inc.
January Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services January Therapeutics, Inc. provides biotechnology services. The company was founded by Robin Jackman and Neil Raheja and is headquartered in San Diego, CA. | 8 years |
| Gene Hung | M | - |
Xinthera, Inc.
Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | 3 years |
| James Tananbaum | M | 60 |
Xinthera, Inc.
Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | - |
| Carl Gordon | M | 59 |
Xinthera, Inc.
Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | - |
| Anand Mehra | M | 48 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| Niall O'Donnell | M | 51 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| Gary Becker | M | - |
The University of Chicago
| 32 years |
| Jason Kahana | M | - |
January Therapeutics, Inc.
January Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services January Therapeutics, Inc. provides biotechnology services. The company was founded by Robin Jackman and Neil Raheja and is headquartered in San Diego, CA. | - |
| Michael Rome | M | - |
Xinthera, Inc.
Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | 3 years |
| David Mizrahi | M | - |
January Therapeutics, Inc.
January Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services January Therapeutics, Inc. provides biotechnology services. The company was founded by Robin Jackman and Neil Raheja and is headquartered in San Diego, CA. | - |
| Paul Bien | M | - |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| Deborah Baron | F | 55 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David A. Graham | M | - |
Indiana University
| 9 years |
| Rodney Lappe | M | 69 | 7 years | |
| John T. Hackett | M | 89 |
Indiana University
| 3 years |
| Elizabeth O'Farrell | F | 59 |
Indiana University
| 5 years |
| Elisabeth K. Evans | F | 61 |
Indiana University
| 6 years |
| John Inwood | M | - |
Indiana University
| 4 years |
| Ed J. Powers | M | - |
The University of Chicago
| 3 years |
| Alan L. Montgomery | M | - |
The University of Chicago
| - |
| Keith Woodward | M | 60 |
Indiana University
| 4 years |
| Eric Baer | M | - |
Indiana University
The University of Chicago
| 7 years |
| Alok Gaur | M | - |
The University of Chicago
| 6 years |
| Neil Reisman | M | 62 | 1 years | |
| Rachael S. Wexler | F | - |
The University of Chicago
| 4 years |
| Daniel J. Young | M | - |
The University of Chicago
| 4 years |
| Daniel Peterson | M | - |
Indiana University
| 7 years |
| Stephen M. McConnell | M | - |
The University of Chicago
| 1 years |
| Sara Zaknoen | M | 65 |
Adastra Pharmaceuticals, Inc.
 Adastra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Adastra Pharmaceuticals, Inc. engages in the provision of clinical and commercial development of proprietary drugs for the treatment of various cancers. The company was founded by Tracy L. Parrott in 2005 and is headquartered in Princeton, NJ.
Cabrellis Pharmaceuticals Corp.
 Cabrellis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ. | 5 years |
| Lori G. Roberts | F | 63 |
Indiana University
| 7 years |
| Greg S. Norrod | M | - |
Indiana University
| 3 years |
| Sarvjeev S. Sidhu | M | - |
Indiana University
| 4 years |
| Tracy Lawhon Parrott | F | - |
Adastra Pharmaceuticals, Inc.
Adastra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Adastra Pharmaceuticals, Inc. engages in the provision of clinical and commercial development of proprietary drugs for the treatment of various cancers. The company was founded by Tracy L. Parrott in 2005 and is headquartered in Princeton, NJ. | 2 years |
| Temre Johnson | M | - | 5 years | |
| Reena Desai | F | - | - | |
| Michael Booth | M | - |
The University of Chicago
| 7 years |
| Isaac Barchas | M | 56 |
The University of Chicago
| - |
| Maya Martinez-Davis | F | 54 | 6 years | |
| Peggy Hebard | F | 50 |
Coopers & Lybrand Consulting, Inc.
| - |
| Aaron Davis | M | 45 | 6 years | |
| Magesvaran Suranjan | M | 54 |
The University of Chicago
Indiana University
| 7 years |
| Matthew J. Becker | M | - |
Indiana University
| 7 years |
| Zhong-Yin Zhang | M | - |
Aarden Pharmaceuticals, Inc.
 Aarden Pharmaceuticals, Inc. BiotechnologyHealth Technology Aarden Pharmaceuticals, Inc. operated as a drug discovery and biotechnology company. The company was founded by Thomas M. Estok, Christopher C. LeMasters, Francis Burrows and Zhong-Yin Zhang in 2008 and was headquartered in Indianapolis, GA. | - |
| Kamlesh Rath | M | - |
Indiana University
| 6 years |
| Carla N. Taylor | F | - |
The University of Chicago
| 6 years |
| Luis Garicano Gabilondo | M | - |
The University of Chicago
| 4 years |
| Joseph Werne | M | - |
The University of Chicago
| 4 years |
| Francis Burrows | M | - |
Aarden Pharmaceuticals, Inc.
Aarden Pharmaceuticals, Inc. BiotechnologyHealth Technology Aarden Pharmaceuticals, Inc. operated as a drug discovery and biotechnology company. The company was founded by Thomas M. Estok, Christopher C. LeMasters, Francis Burrows and Zhong-Yin Zhang in 2008 and was headquartered in Indianapolis, GA. | - |
| Federico L. Kaune | M | - |
The University of Chicago
| 4 years |
| Anand Deshpande | M | 62 |
Indiana University
| 4 years |
| Rob Barnard | M | 56 |
Indiana University
| 7 years |
| William Ringo | M | 78 | 2 years | |
| Peter Kagan | M | 73 |
The University of Chicago
| 3 years |
| Michael Grey | M | 71 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 6 years |
| Julie Cherrington | M | 66 | 5 years | |
| James R. Schmidt | M | 63 |
Conforma Therapeutics Corp.
 Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | - |
| David Cheng | M | - |
The University of Chicago
| 4 years |
| Jong-Suk Ye | M | 70 |
Indiana University
| 3 years |
| Bruce E. Beerbower | M | - |
Indiana University
| 5 years |
| Michael Fonstein | M | 64 |
The University of Chicago
| 4 years |
| John E. Crawford | M | 69 |
Conforma Therapeutics Corp.
Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA.
Cabrellis Pharmaceuticals Corp.
Cabrellis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ. | - |
| Frank D. Gordon | M | - |
The University of Chicago
| 4 years |
| Christopher Kravas | M | 58 |
The University of Chicago
Indiana University
| 7 years |
| Faheem Hasnain | M | 65 | 5 years | |
| William C. Stern | M | 60 |
The University of Chicago
| 3 years |
| Thomas Estok | M | - |
Aarden Pharmaceuticals, Inc.
Aarden Pharmaceuticals, Inc. BiotechnologyHealth Technology Aarden Pharmaceuticals, Inc. operated as a drug discovery and biotechnology company. The company was founded by Thomas M. Estok, Christopher C. LeMasters, Francis Burrows and Zhong-Yin Zhang in 2008 and was headquartered in Indianapolis, GA. | - |
| Bryan John Bailey | M | - |
Indiana University
The University of Chicago
| 7 years |
| Julio A. Delgado | M | - |
The University of Chicago
| 2 years |
| Stacy Pak | F | - |
The University of Chicago
| 2 years |
| Nicholas Swenson | M | 55 |
The University of Chicago
| 2 years |
| Giorgio de Santis | M | - |
The University of Chicago
| 3 years |
| Gregory Solomon | M | - |
The University of Chicago
| 3 years |
| Joshua Chad Leibowitz | M | 53 |
The University of Chicago
| 4 years |
| Seth Weingram | M | - |
The University of Chicago
| 4 years |
| Hugh Kim | M | - |
The University of Chicago
| 4 years |
| Nicholas Marsh | M | - |
The University of Chicago
| 3 years |
| William M. Muckian | M | 64 |
The University of Chicago
| 2 years |
| David Mack | M | 62 |
The University of Chicago
| 3 years |
| Daniel Kazan | M | - |
The University of Chicago
| 3 years |
| Henry J. Shih | M | - |
The University of Chicago
| 4 years |
| Aaron Walter Yeary | M | 49 |
The University of Chicago
| 4 years |
| John Gannon | M | - |
The University of Chicago
| 2 years |
| Atish Gude | M | 59 |
The University of Chicago
| 2 years |
| Terry Kontos | M | - |
The University of Chicago
| 4 years |
| Pete Stevens | M | - |
The University of Chicago
| 2 years |
| Michael D. Ilagan | M | 57 |
The University of Chicago
| 1 years |
| Jeff Mihalek | M | - |
The University of Chicago
| 4 years |
| Evan Scott Flecker | M | - |
The University of Chicago
| 4 years |
| Linda Zuckerman | M | - |
The University of Chicago
| 3 years |
| Henry Park | M | - |
The University of Chicago
| 4 years |
| Gregory J. Haygood | M | - |
The University of Chicago
| 4 years |
| Daniel Bibb Coleman | M | 59 |
The University of Chicago
| 2 years |
| Chang-Hyun Yun | M | 63 |
The University of Chicago
| 3 years |
| Joseph Eandi | M | - |
The University of Chicago
| 3 years |
| Cindy Galiano | F | 49 |
The University of Chicago
| 4 years |
| Mark R. Fitzgerald | M | - |
The University of Chicago
| 2 years |
| Bob Pratt | M | - |
The University of Chicago
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Chris LeMasters
- Personal Network
